Jazz took a step forward with the Chimerix acquisition that should further diversify its revenue base. Read why JAZZ stock is ...

Alnylam Pharmaceuticals (NasdaqGS:ALNY) announced its plan to present new data from its transthyretin amyloidosis (TTR) franchise at the Heart Failure 2025 Congress, alongside securing broader ...

Coherus BioSciences has completed the sale of its Udenyca (pegfilgrastim-cbqv) franchise to Intas Pharmaceuticals under an asset purchase agreement signed by the companies in December 2024 for up ...

After consecutive setbacks at the FDA, Regeneron's string of recent troubles with its Eylea franchise is continuing to pull down the drugmaker. Over the first three months of 2025, Regeneron's ...

Portfolio Receipts growth of 17% to $839 million; Royalty Receipts growth of 12%Net cash provided by operating activities of $596 millionRaised full year 2025 guidance: Portfolio Receipts expected to ...